| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442579 | European Journal of Cancer | 2015 | 7 Pages |
Abstract
CP and CD were equally effective treatment regimens for patients with very platinum-sensitive ROC. The favourable risk-benefit profile suggests carboplatin-PLD as treatment of choice for these patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sven Mahner, Werner Meier, Andreas du Bois, Chris Brown, Domenica Lorusso, Tiziana Dell'Anna, Jacques Cretin, Hanne Havsteen, Paul Bessette, Alain G. Zeimet, Ignace Vergote, Paul Vasey, Eric Pujade-Lauraine, Laurence Gladieff, Annamaria Ferrero,